Merck
  • Home
  • Search Results
  • Evaluation of serum fetuin-A relationships with biochemical parameters in patients on hemodialysis.

Evaluation of serum fetuin-A relationships with biochemical parameters in patients on hemodialysis.

Clinical and experimental nephrology (2007-12-19)
Osamu Oikawa, Terumi Higuchi, Toshio Yamazaki, Chii Yamamoto, Noboru Fukuda, Koichi Matsumoto
ABSTRACT

Complications associated with atherosclerosis in dialysis patients are attracting attention. Fetuin-A, a circulating calcium-regulatory glycoprotein that inhibits vascular calcification, is associated with inflammation and outcome in dialysis patients. In this study, the relation between serum fetuin-A concentration and biochemical parameters in patients on hemodialysis was investigated. Forty hemodialysis patients, 22 men and 18 women, aged 57 +/- 12 years; and 20 controls, 10 men and 10 women, aged 50 +/- 10 years, participated in this study. We measured serum fetuin-A by enzyme-linked immunosorbent assay. The biochemical parameters of serum albumin, alkaline phosphatase, calcium, phosphate, intact parathyroid hormone, total cholesterol, triglyceride, lipoprotein (a), brain natriuretic peptide (BNP), highly sensitive C-reactive protein (hsCRP), hemoglobin, and hematocrit in whole blood were also measured before starting dialysis sessions. Other parameters included the cardio ankle vascular index, age, mean arterial pressure, total weekly urea clearance (Kt/V), smoking habit, body mass index (BMI), and duration of dialysis. These variables were included in simple regression analysis. Levels of serum fetuin-A in the hemodialysis patients (331 +/- 55 microg/ml) were significantly lower than those in the healthy controls (361 +/- 55 microg/ml; P < 0.05). There was a negative correlation between serum fetuin-A levels and duration of dialysis (r = -0.37, P < 0.01), BNP (r = -0.37, P < 0.001), and hsCRP (r = -0.40, P < 0.01), and a positive association with serum albumin (r = 0.31, P < 0.05). These data suggest that a low fetuin-A level is a useful predictor of malnutrition and inflammation, as well as being a useful predictor of the cardiac failure caused by an increased ventricular load in hemodialysis patients.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Zinc, powder, <150 μm, 99.995% trace metals basis
Sigma-Aldrich
Zinc, foil, thickness 0.25 mm, 99.9% trace metals basis
Sigma-Aldrich
Zinc, mossy, ≥99%
Sigma-Aldrich
Betaine, ≥98% (perchloric acid titration)
Sigma-Aldrich
Zinc, wire, diam. 1.0 mm, 99.995% trace metals basis
Sigma-Aldrich
DL-Homocysteine, ≥95% (titration)
Sigma-Aldrich
Zinc, purum, powder
Sigma-Aldrich
Zinc, granular, 30-100 mesh, 99%
Sigma-Aldrich
Betaine, BioUltra, ≥99.0% (NT)
Sigma-Aldrich
Xanthurenic acid, 96%
Sigma-Aldrich
p-Cresol, puriss. p.a., ≥99.0% (GC)
Supelco
Glycolic acid, certified reference material, TraceCERT®
Sigma-Aldrich
p-Cresol, 99%
Supelco
trans-4-Hydroxy-L-proline, analytical standard
Sigma-Aldrich
Oxalic acid, purified grade, 99.999% trace metals basis
Sigma-Aldrich
Zinc, shot, 99.9999%
Sigma-Aldrich
Phthalic acid, reagent grade, 98%
Sigma-Aldrich
Glycolic acid solution, high purity, 70 wt. % in H2O
Sigma-Aldrich
Glycolic acid, ReagentPlus®, 99%
Sigma-Aldrich
Zinc, mossy, 99.99% trace metals basis
Sigma-Aldrich
Zinc, dust, <10 μm, ≥98%
Sigma-Aldrich
Oxalic acid, 98%
Sigma-Aldrich
Phthalic acid, ACS reagent, ≥99.5%
Sigma-Aldrich
Glycolic acid solution, technical grade, 70 wt. % in H2O
Sigma-Aldrich
L-Proline, 99%, FCC, FG
Sigma-Aldrich
Zinc preparation, 5 g/dL Zn+2 in THF, highly reactive Rieke®metal
Sigma-Aldrich
Zinc, nanopowder, 40-60 nm avg. part. size, ≥99% trace metals basis
Supelco
4-Methylphenol solution, certified reference material, 5000 μg/mL in methanol
Sigma-Aldrich
trans-4-Hydroxy-L-proline, ≥99%
Sigma-Aldrich
trans-4-Hydroxy-L-proline, BioReagent, suitable for cell culture, ≥98.5%